Serina's SER-252 Puts a Practical Innovation at the Center of the Story
Biotechnology often commands attention by promising an entirely new molecule. Serina Therapeutics (NYSE American: SER) is pursuing a different proposition: take an established therapeutic agent, improve how it reaches the patient and…
Serina Therapeutics, Inc. (NYSE American: SER) is approaching a consequential clinical milestone with SER-252, its long-acting POZ-apomorphine candidate for advanced Parkinson’s disease, now advancing into Cohort 2 of a registrational Phase 1b study. For many, the appeal is not simply that Serina is pursuing…
Serina Therapeutics, Inc. (NYSE American: SER) has moved its lead Parkinson’s disease program from promise on paper to progress in patients. After an independent safety committee completed its blinded review of the first cohort in the Company’s Phase 1b registrational study, Serina received…
